Envestnet Asset Management’s Virtus Biotech Clinical Trials ETF BBC Stock Holding History
Bought
Maintained
Sold
Other funds holding BBC
Envestnet Asset Management's BBC Position: Q3 2026 in Review
Envestnet Asset Management sold out of Virtus Biotech Clinical Trials ETF (BBC) in Q3 2026, closing a stake of 4,448 shares — an estimated $234K sold.
Envestnet Asset Management first reported a position in BBC in Q4 2016 and held it in 13 quarters. The position peaked at $6.76M in Q2 2018. 17 funds tracked by Wall St. Rank hold BBC as of Q3 2026.
- Envestnet Asset Management reported no remaining Virtus Biotech Clinical Trials ETF position as of Q3 2026 after selling out during the quarter.
- Envestnet Asset Management sold 4,448 Virtus Biotech Clinical Trials ETF shares in Q3 2026, an estimated $234K.
- Envestnet Asset Management first reported a position in Virtus Biotech Clinical Trials ETF in Q4 2016 and held it in 13 quarters.
- Envestnet Asset Management's Virtus Biotech Clinical Trials ETF position peaked at $6.76M in Q2 2018.
- 17 funds tracked by Wall St. Rank held Virtus Biotech Clinical Trials ETF as of Q3 2026.
Based on Envestnet Asset Management's 13F filing for Q3 2026, filed 16 Nov 2026.